These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32553245)

  • 1. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.
    Java A
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):128-137. PubMed ID: 32553245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
    Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M
    Nephron; 2020; 144(11):537-549. PubMed ID: 32950988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
    Raina R; Krishnappa V; Blaha T; Kann T; Hein W; Burke L; Bagga A
    Ther Apher Dial; 2019 Feb; 23(1):4-21. PubMed ID: 30294946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
    Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
    PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.
    González CC; López-Jiménez V; Vázquez-Sánchez T; Vázquez-Sánchez E; Cabello M; Hernández-Marrero D
    Transplant Proc; 2022; 54(1):25-26. PubMed ID: 34906374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M; Go RS; Willrich MAV
    J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
    Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
    Zuber J; Le Quintrec M; Krid S; Bertoye C; Gueutin V; Lahoche A; Heyne N; Ardissino G; Chatelet V; Noël LH; Hourmant M; Niaudet P; Frémeaux-Bacchi V; Rondeau E; Legendre C; Loirat C;
    Am J Transplant; 2012 Dec; 12(12):3337-54. PubMed ID: 22958221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Noris M; Remuzzi G
    Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.